000 04185nam a22004095i 4500
001 100382
003 DE-He213
005 20230102112952.0
007 cr nn 008mamaa
008 180313s2018 gw | s |||| 0|eng d
020 _a9783319735856
_9
024 7 _a10.1007/978-3-319-73585-6
_2doi
040 _aES-MaUEC
_bspa
050 4 _aRC935.M8 2018 EB
245 1 0 _aMyasthenia Gravis and Related Disorders
_cedited by Henry J. Kaminski, Linda L. Kusner.
250 _a3rd edition
264 1 _aCham
_bSpringer International Publishing
_bSpringer International Publishing
_c2018.
300 _a1 recurso en línea (XIII, 353 páginas 52 ilustraciones, 15 ilustraciones a color)
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aCurrent Clinical Neurology
_x1559-0585
505 0 _aChapter 1. Neuromuscular Junction Physiology and Pathophysiology -- Chapter 2. Acetylcholine Receptor Structure -- Chapter 3. Immunopathogenesis of Myasthenia Gravis -- Chapter 4. Animal Models of Myasthenia Gravis for Preclinical Evaluation -- Chapter 5. Epidemiology and Genetics of Myasthenia Gravis -- Chapter 6. Clinical Presentations of Myasthenia Gravis -- Chapter 7. Ocular Myasthenia -- Chapter 8. Thymoma-associated Myasthenia Gravis -- Chapter 9. Electrodiagnosis of Neuromuscular Junction Disorders -- Chapter 10. Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases -- Chapter 11. Treatment of Myasthenia Gravis -- Chapter 12. Neurocritical Care of Myasthenic Crisis -- Chapter 13. Thymectomy for Non-thymomatous Myasthenia Gravis -- Chapter 14. Lambert-Eaton Syndrome -- Chapter 15 Acquired Neuromyotonia -- Chapter 16. Congenital Myasthenic Syndromes -- Chapter 17. Toxic Neuromuscular Transmission Disorders -- Chapter 18. Predictors of Psychological Health in Myasthenia Gravis -- Chapter 19. Myasthenia Gravis: Classification and Outcome Measurements -- Chapter 20. Emerging Therapeutics for Myasthenia Gravis -- Chapter 21. Clinical Trial Design for Myasthenia Gravis.
520 3 _aThe third edition of this important, gold-standard title outlines a range of significant advances in the study and understanding of myasthenia gravis. The overarching goal of this new edition is identical to the first and second -- to provide the clinician and the scientist with a common resource for understanding the profound achievements in the clinical, translational, and basic sciences of neuromuscular transmission disorders. In addition to several new authors and an extensive update of all chapters, this third edition includes summaries of pre-clinical research standards for autoimmune MG, along with a broad summary of MG clinical trial performance. The now greater understanding of the clinical presentation of MuSK-related MG and identification of potential new autoantigens, including LRP-4, is discussed. The development of treatment guidelines by groups in Japan, the United Kingdom, Germany, and an international consortium is also outlined. Myasthenia Gravis and Related Disorders, Third Edition, is an invaluable resource for meeting the many and varied needs of clinicians who treat patients with myasthenia gravis.
650 7 _aNeurología
_2embne
_9139040
650 7 _aMiastenia grave
_9667117
_2embne
700 1 _aKaminski, Henry J.
_eeditor literario
_0http://id.loc.gov/authorities/names/n2002016630
_0http://viaf.org/viaf/22368208
_988068
700 1 _aKusner, Linda L.
_eeditor literario
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_0http://viaf.org/viaf/148105729
_9106996
776 0 8 _iEdición impresa:
_z9783319735849
776 0 8 _iEdición impresa:
_z9783319735863
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-73585-6
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490 0 _aMedicine (Springer-11650)
988 _aSpringer_Medicine_2018
998 _b01/2019
_dz
_ea
_feng
_ggw
_h0
999 _c100382
_d100382
_x1